Hepatitis B virus reactivation during fludarabine therapy in non-Hodgkin's lymphoma.
Yavuz
Sinan
S
Department of Oncology, Faculty of Medicine, Cukurova University, Balcali, Adana, Turkey. siyav@cu.edu.tr
Paydas
Semra
S
Disel
Umut
U
Sahin
Berksoy
B
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004248:DNA (Cytosine-5-)-Methyltransferases / Q000037:antagonists & inhibitors; D004279:DNA, Viral / Q000032:analysis; D006509:Hepatitis B / Q000188:drug therapy / Q000209:etiology*; D006515:Hepatitis B virus / Q000502:physiology*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000821:virology; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D014740:Vidarabine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014775:Virus Activation / Q000187:drug effects*
D000970:Antineoplastic Agents; D004279:DNA, Viral; D019259:Lamivudine; D004248:DNA (Cytosine-5-)-Methyltransferases; D014740:Vidarabine; C024352:fludarabine